Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma

Efrat Markus, Svetlana Trestman, Yael Cohen, Yoel Angel, Yael Sofer, Moshe Mittelman, Irit Avivi, Naftali Stern, Elena Izkhakov*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Background: The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among patients with smoldering MM (SMM). Methods: Changes in various components of metabolic syndrome were investigated during the follow-up of patients with either MM or SMM compared to healthy controls. The data of 153 patients (105 with MM and 48 with SMM) and 138 controls were accessed from our medical center's records between 2008 and 2015. We analyzed the patients' data at diagnosis (baseline) and after 1, 3, and 5 years of follow-up. Results: Patients with SMM had a significantly higher prevalence of diabetes, hypertension, and dyslipidemia at baseline compared to controls. A multivariate Cox regression analysis revealed a higher risk to develop dyslipidemia after 1, 3, and 5 years of follow-up among the SMM patients. The MM patients had a higher risk to develop diabetes after 1 year, hypertension after 5 years, and dyslipidemia after 1, 3, and 5 years of follow-up. Conclusions: These data demonstrate that patients with SMM and those with MM are more prone to develop various components of metabolic syndrome, and they stress the importance of following-up metabolic syndrome components in both groups of patients.

Original languageEnglish
Article number489
JournalBMC Cancer
Volume20
Issue number1
DOIs
StatePublished - 30 May 2020

Funding

FundersFunder number
UK Research and Innovation48752

    Keywords

    • Hyperlipidemia
    • Metabolic changes
    • Smoldering multiple myeloma

    Fingerprint

    Dive into the research topics of 'Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma'. Together they form a unique fingerprint.

    Cite this